Airway Therapeutics Announces FDA Acceptance of IND for AT-100’s Second Indication in Severe COVID-19 Patients
Initiating Phase 1b clinical trial with initial results expected 3Q2021 Potential for novel therapeutic AT-100 to inhibit viral replication, promote viral elimination and reduction of lung injury, inflammation, and secondary infections in severe COVID-19 patients Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation […]